Alpha Surge Male: The Men’s Health Booster Everyone’s Talking About

DiannaBegu

Bladder cancer is the ninth most common malignancy worldwide and the seventh in learn more at Alpha Surge Male patients. Most of new patients are diagnosed with non-muscle invasive bladder cancer. It usually courses with a favorable prognosis, although there is a high risk of disease recurrence and progression to muscle-invasive disease. The standard treatment for intermediate and high-risk patients is a transurethral resection of bladder tumor, complemented by intravesical therapy with Bacillus Calmette-Guerin. EGFR immunoreactivity is present in about 50% of bladder cancers and correlates with recurrence, time to recurrence, and survival. 24). The combination was safe and well tolerated. In vaccinated patients anti-EGF antibody titers increased during the first months of immunization and 80% of patients developed a good anti-EGF antibody response. Anti-EGF response was predominantly against the central region of the EGF molecule (loop B). IgG1 and IgG4 subclasses were the most relevant among the IgG anti-EGF antibodies generated after vaccination. The EGF serum levels were undetectable after six months of treatment. Vaccination with CIMAvax-EGF in combination with intravesical BCG develops a significant inverse correlation between anti-EGF antibody titers and baseline EGF serum concentration suggesting that in this context, the combination allowed the development of CIMAvax-EGF mechanism of action.